97 related articles for article (PubMed ID: 28435225)
1. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
Woo HI; Kim SR; Huh W; Ko JW; Lee SY
Drug Des Devel Ther; 2017; 11():1135-1146. PubMed ID: 28435225
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH; Tarkiainen EK; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Klein K; Schwab M; Backman JT; Tornio A; Niemi M
Clin Pharmacol Ther; 2024 Jun; 115(6):1428-1440. PubMed ID: 38493369
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.
Chen WQ; Shu Y; Li Q; Xu LY; Roederer MW; Fan L; Wu LX; He FZ; Luo JQ; Tan ZR; He YJ; Zhou HH; Chen X; Zhang W
PLoS One; 2013; 8(8):e70341. PubMed ID: 23940561
[TBL] [Abstract][Full Text] [Related]
5. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
[TBL] [Abstract][Full Text] [Related]
6.
Wagner JB; Abdel-Rahman S; Raghuveer G; Gaedigk A; Boone EC; Gaedigk R; Staggs VS; Reed GA; Zhang N; Leeder JS
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254988
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and genetic analysis of four children with Rotor syndrome].
Tan Y; Ouyang W; Jiang T; Tang L; Zhang H; Yu Y; Qin X; Li S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Jun; 41(6):715-719. PubMed ID: 38818556
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
Cho CK; Mo JY; Ko E; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Feb; 47(2):95-110. PubMed ID: 38159179
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of single-dose oral atorvastatin and its metabolites support therapeutic use in orange-winged Amazon parrots (Amazona amazonica).
Mikoni N; Guzman DS; Knych H; Beaufrère H
Am J Vet Res; 2024 Jan; 85(1):. PubMed ID: 38029520
[TBL] [Abstract][Full Text] [Related]
10. Transporter Genes and statin-induced Hepatotoxicity.
Choi SA; Kim JS; Park YA; Lee DH; Park M; Yee J; Chang Y; Song TJ; Gwak HS
Cardiovasc Drugs Ther; 2024 May; ():. PubMed ID: 38809397
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E; Haufroid V; Deldicque L; Balligand JL; Elens L
Clin Biochem; 2024 Feb; 124():110707. PubMed ID: 38182100
[TBL] [Abstract][Full Text] [Related]
12. Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin.
Krohmer E; Rohr BS; Stoll F; Gümüs KS; Bergamino M; Mikus G; Sauter M; Burhenne J; Weiss J; Meid AD; Czock D; Blank A; Haefeli WE
Cardiovasc Drugs Ther; 2023 Dec; ():. PubMed ID: 38112932
[TBL] [Abstract][Full Text] [Related]
13. Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats.
Wu F; Cui M; Wang S; Yu C; Yin W; Li J; Yan X
Xenobiotica; 2023 Dec; 53(12):644-652. PubMed ID: 38054840
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure.
Hoa PQ; Kim HK; Jang TW; Seo H; Oh JY; Kim HC; Shin AY; Min J; Jayanti RP; Hung TM; Anh NK; Ahn S; Long NP; Cho YS; Shin JG;
Int J Antimicrob Agents; 2024 Feb; 63(2):107034. PubMed ID: 37977236
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of single-dose oral atorvastatin and its metabolites support therapeutic use in cockatiels (Nymphicus hollandicus).
Mitchell M; Guzman DS; Knych H; Beaufrère H
Am J Vet Res; 2024 Apr; ():1-7. PubMed ID: 38626797
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between regorafenib and atorvastatin in rats.
Szkutnik-Fiedler D; Szałek E; Otto F; Czyrski A; Karaźniewicz-Łada M; Wolc A; Grześkowiak E; Lewandowski K; Karbownik A
Pharmacol Rep; 2024 Apr; ():. PubMed ID: 38632186
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review.
Yow HY; Ikawati M; Siswanto S; Hermawan A; Rahmat AK; Tan JS; Tee YC; Ng KP; Ikawati Z
Pharmacogenomics; 2024 May; ():1-30. PubMed ID: 38884938
[TBL] [Abstract][Full Text] [Related]
18. Effect of
Herrera-González S; Martínez-Treviño DA; Aguirre-Garza M; Gómez-Silva M; Barrera-Saldaña HA; León-Cachón RBR
Biomed Rep; 2017 Dec; 7(6):579-584. PubMed ID: 29250329
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Synthesis and Analysis of Atorvastatin and its Intermediates.
Li SF; Zhang W; Zhang W; Huang A; Zhu JQ; Wang YJ; Zheng YG
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37828675
[TBL] [Abstract][Full Text] [Related]
20. The effect of
Wang Y; Tian Y; Lv P; Chen L; Luo W; Jing X; Li H; Tan Z; Wang Y; Zhou H; Ouyang DS
Pharmazie; 2017 Jun; 72(6):365-368. PubMed ID: 29442027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
